Onika T. Murray, Ph.D.
Affiliations: | 2012 | Molecular and Cellular Pharmacology | Stony Brook University, Stony Brook, NY, United States |
Area:
Pharmacology, Molecular BiologyGoogle:
"Onika Murray"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Basil Rigas | grad student | 2012 | SUNY Stony Brook | |
| (Phospho-Sulindac Inhibits Pancreatic Cancer Growth: The Role of NFATc1.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Murray OT, Wong CC, Vrankova K, et al. (2014) Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International Journal of Oncology. 44: 521-9 |
| Xie G, Nie T, Mackenzie GG, et al. (2012) The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. British Journal of Pharmacology. 165: 2152-66 |
| Murray OT, Vrankova K, Johnson F, et al. (2012) Abstract 4431: NFATc1 silencing increases sensitivity of pancreatic cancer cells to phosphosulindac Cancer Research. 72: 4431-4431 |
| Zhao W, Mackenzie GG, Murray OT, et al. (2009) Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30: 512-9 |